“Life-Changing Technology You Can Trust” – this is the mission and promise of StemCord, using science-based research, global expertise, and proven methodology. In its 20th year, the company remains committed to harnessing the potential of regenerative medicine to build hope and safeguard your child and family’s future.
StemCord SG Phils. Corporation has been the pioneer in providing cord blood banking services to families in the Philippines, through StemCord in Singapore. Director and Co-founder, Dr Leong See Odd said, “The acquisition of the StemCord office in the Philippines and the move into a new and bigger space at the High Pointe Medical Hub in Mandaluyong City, is in line with StemCord’s objectives of expanding regionally. This will also bring StemCord closer to meet the needs of the parents in the Philippines.”
Building on StemCord’s science-based approach and technological expertise, we are also launching #itslifechanging campaign, focused on educating parents on the science and benefits of cord blood banking. Dr Ang Peng Tiam, Director and Co-founder of StemCord, further explained, “This campaign aims to educate the next generation, including children of our clients, helping them tap on the next wave of medical advances.”
Dr Teo Cheng Peng, Chairman & Co-founder of StemCord, “There are many cord blood banks around the world, but there will always be special and high-quality ones that doctors, nurses, and midwives will speak highly of. StemCord belongs to this elite group of distinguished facilities. We have adopted standards beyond the legal requirements of the Ministry of Health, Singapore, and the stringent criteria of International Cord Blood Banking practice. We voluntarily seek to be accredited by NetCord-FACT over the years to adhere to the highest international standards in Cord Blood Banking.”
StemCord SG Philippines’ Chief Operating Officer, Phoebe Te shares, “Through the years, Filipinos have been recognizing the benefits of stem cell science and cord blood banking. In the past few years, we’ve seen a dramatic shift in outlook, giving more emphasis to health and disease prevention. We’re seeing this evolution among Filipinos, which corresponds with our mission as a company to provide life-changing technology guided by medical knowledge with the purpose of promoting and improving health.”
Capturing the present for the future
In our journey in the healthcare industry, we have seen how stem cells therapy have saved and improved lives. Studies now show that one in 217 people will have a stem cell transplant by the age of 70. To date, over 40,000 cord blood transplants have taken place worldwide1.
Cord Blood Banking is when newborn umbilical cord blood is collected and stored at birth. It is a rich source of Stem Cells – mainly Haematopoietic Stem Cells (HSCs). HSCs have been used to treat more than 80 life-threatening diseases including bone marrow disorders, leukemias and lymphomas, blood cancers, and autoimmune diseases.
Current studies of stem cells focus on its role in the treatment of autism. Clinical trials have shown promising results on the treatment of autism. Scientists at Duke University in US reported results from a small, early-stage study of an experimental autism therapy for children using their own umbilical cord blood. Phase I trial results were published in April 2017 in the journal Stem Cells Translational Medicine and shows that among 25 children ages 2 to 5, more than two-thirds appeared to show improvements in speech, socialization, and eye contact, as reported by parents and assessed by researchers3. KK Women’s and Children’s Hospital, Singapore is also running a clinical trial on umbilical cord blood for the treatment of Autism (ASD), and some of StemCord clients have participated in this trial.
In 2015, StemCord introduced Cord Stem Cells Banking, stem cells extracted from the umbilical cord, are cultured, and stored. These unique stem cells are known as Mesenchymal Stem Cells (MCSs). Research indicates that the Mesenchymal Stem Cells (MSCs) found in the umbilical cord tissue, have the unique ability to rapidly regenerate and differentiate themselves into various tissues and organ cells, including heart, nerve, cartilage, bone, muscle, liver, cartilage, and fat tissue. The use of Cord Mesenchymal Stem Cells for treatments is still in the clinical trial phase, but they have great potential for future use in the treatment of conditions such as heart disease, diabetes, strokes, spinal cord injuries, and more. Currently, there are more than 1,000 ongoing clinical trials involving MSCs, and more than 6,000 articles are published4, which further emphasize the potential for MSCs in future Stem Cell therapies.
A study was conducted by the National University of Singapore (NUS) on the use of Mesenchymal Stem Cells in treatment and to regenerate damaged cartilage in the osteoarthritic knee. The study concluded high success rate in cartilage regeneration among people suffering from this condition.5
Indeed, these are exciting times in the science of stem cell treatment, opening new beginnings and hope for healing in many diseases.
So, whether you’re a parent welcoming a new life to the world or simply one who cares for the future, investing in cord blood and cord stem cell banking can be an invaluable investment for the family.
StemCord is Southeast Asia’s first NetCord-FACT (Foundation for the Accreditation of Cellular Therapy) accredited cord blood bank in Singapore and has been awarded NetCord-FACT accreditation four times – in years 2011, 2014, 2017, and 2021. NetCord-FACT is a recognised and prestigious international accrediting organization that develops and promotes global standards for high quality Cord Blood collection, processing, testing, banking, selection, and release. StemCord is audited and licensed as an autologous private cord blood bank by the Ministry of Health (MOH) in Singapore. It was the first cord blood bank to be licensed by the Ministry of Health in 2002. Today, StemCord has stored more than 45,000 samples of cord blood. StemCord’s headquarters is in Singapore and it has offices in Indonesia and the Philippines.
StemCord is founded by a group of doctors in 2002.
Dr. Teo Cheng Peng
Haematologist & Physician
MBBS (Singapore)M.Med (Internal Medicine)FAMS (Haematology)
Dr. Ang Peng Tiam
Medical Oncologist & Physician
M.Med (Internal Medicine)
FAMS (Medical Oncology)
MRCP (United Kingdom)
Nephrologist & Physician
M.Med (Internal Medicine)
FAMS (Renal Medicine)
MRCP (United Kingdom)
*Founders full profile: https://www.stemcord.com/about/
For more information, visit www.stemcord.com.ph, or follow @stemcordph on Instagram and Facebook. To set an appointment, call 8723-2333 or email [email protected] StemCord Philippines’ office is located in Units 201-202 High Pointe Medical Hub, 241 Shaw Boulevard cor. M. Yulo Street, Brgy. Bagong Silang, Mandaluyong City.
This is a press release distributed by Visions and Expressions